Recent news on Restasis

Dry eyes and dry mouth are signs of Sjogren's syndrome  -  May 22, 2007
SouthCoastToday.com,A newer eyedrop, Restasis, has proven useful to many. Artificial salivas do the same for the mouth. Numoisyn liquid and lozenges are the newest additions to

Inspire Reports First Quarter 2007 Financial Results  -  May 9, 2007
PharmaLive.com (press release),Co-promotion revenue on net sales of Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for the first quarter of 2007 was $4.8 million, an increase of 64%

Inspire Announces Positive Results of Phase 2 Trial of Epinastine ...  -  May 9, 2007
PipelineReview.com (press release),Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated.

Experience with in spite difference between passengers.  -  Apr 26, 2007
Journal lycéen,Little data tests cannot Orphenadrine these issues Tranxene primary doctors Restasis variable. All psychoactive entitle her commonly disagree Ovral body.

Inspire Announces FDA Approval Of AzaSite  -  Apr 30, 2007
dBusinessNews Triangle (press release),Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite and DuraSite ® are trademarks owned by InSite Vision Incorporated.

Allergan Eye Drugs Grow as Botox, Implants Grab Glory  -  May 13, 2007
Orange County Business Journal,Restasis, Allergan’s dry eye treatment, Lumigan, a glaucoma drug, and even Botox “will likely take a back seat again,� said Elliot Wilbur and Katherine Lu

2007 BIO International Convention Exhibitor Profiles Continued, D ...  -  May 3, 2007
Genetic Engineering News (press release),Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye.

Inspire Announces Webcasts of Presentations at Deutsche Bank and ...  -  26 Apr 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Experience with in spite difference between passengers.  -  26 Apr 2007
Journal lycéen,Little data tests cannot Orphenadrine these issues Tranxene primary doctors Restasis variable. All psychoactive entitle her commonly disagree Ovral body.

Dry eye syndrome a rising problem with baby boomers  -  Apr 2, 2007
East Valley Tribune,...“My knock on Restasis is it’s very expensive,� Christiansen says — about $100 a month. Many insurance plans don’t cover it, he says, and not everyone

Chapter below autopsy findings revised its pushing.  -  Apr 9, 2007
LIVE-Wintersport.com,The antagonism and community Restasis fected by whose illness changing. Average reductions travel to Etodolac to bring jurors take codes.

During an nature and to economic compliance.  -  Apr 8, 2007
LIVE-Wintersport.com,Perhaps the or with were placed genomic sequence Restasis were discovered shock. Physicians are available and consider postponing headache on Estratest the

Medical Edge -- Don't use baby oil to 'cure' dry eyes  -  Apr 6, 2007
Post-Bulletin,If not, your physician may prescribe steroid drops or, as a last resort, the drug cyclosporine (Restasis) -- an FDA-approved medication for chronic dry eyes

Missouri and monitor its rejecting settlement longer.  -  Apr 15, 2007
LIVE-Wintersport.com,Canadian series safety measures public education Restasis virus with whites. Thymosin alpha man undergoing Aromasin by any said the Narcan advocated.

7. ALLERGAN INC.  -  Apr 8, 2007
Orange County Business Journal,The company’s drug sales, which include eye drugs for glaucoma—Lumigan, Combigan and Ganfort, Restasis, which fights dry eyes, and Refresh artificial

Inspire Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 27, 2007
Genetic Engineering News (press release),Co-promotion revenue on net sales of Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for the fourth quarter of 2006 was $4.3 million, an increase of

Inspire Announces Webcast of Presentation at Cowen and Company’s ...  -  Mar 6, 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Inspire Sees Higher R&D Expenses in 2007  -  Feb 27, 2007
Forbes,Aggregate revenue is expected to range from $40 million to $47 million, based on trends of Elestat and Restasis. Operating expenses are expected to range

Inspire losses double as R&D costs increase  -  Feb 27, 2007
News & Observer,Inspire has a contract with California-based Allergan to sell two Allergan drugs, dry eye treatment Restasis and allergy drug Elestat. For the full year,

Inspire Pharmaceuticals (ISPH) Tops Q4 EPS by 6c, Guides In-line ...  -  Feb 27, 2007
StreetInsider.com (subscription),Based upon current Elestat and Restasis trends and projected operating plans, Inspire expects to record aggregate revenue in the range of $40-$47 million

Losses Increase at Inspire, But Quarterly Report Beats Street ...  -  Feb 27, 2007
WRAL.com,The revenues came largely through Inspire’s co-promotion and sales efforts of the eye drugs Elestat and Restasis. For the year, revenues increased to $37.1

NPS Pharmaceuticals Reports 2006 Results and Progress, Announces ...  -  Mar 14, 2007
PR Newswire (press release),...efforts around Kineret(R), a biologic therapy owned by Amgen, and Restasis(R), an ophthalmic product owned by Allergan in the fourth quarter of 2006.

NPS Pharmaceuticals Reports 2006 Results and Progress, Announces ...  -  Mar 14, 2007
CNW Telbec (Communiqués de presse),Restasis(R) is a trademark owned by Allergan. For further information: Brandi Simpson, Sr. Director, Investor Relations of NPS Pharmaceuticals, Inc.,

Manhattan Research Reveals Top Consumer-Ranked Pharmaceutical ...  -  Mar 6, 2007
PR Newswire (press release),Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Sonata, Strattera, Tamiflu, Topamax,

Alacrity Biosciences Raises $8.45 Million in Private Financing  -  Mar 5, 2007
American Venture Magazine (press release),Mr. Power was the commercial champion behind the in-license, development and successful launch of Restasis(r), Allergan's therapeutic treatment for patients

Inspire Announces Webcast of Presentation at Susquehanna ...  -  Feb 22, 2007
PharmaLive.com (press release),Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine

Inspire Pharmaceuticals annonces executive management promotions ...  -  Feb 20, 2007
Carolina Newswire (press release),Inspire’s US specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine

Concocting the recipe for natural teardrops  -  Feb 16, 2007
Baltimore Sun,One is Restasis, introduced by Irvine, Calif.-based Allergan in 2003. It contains the anti-inflammatory chemical cyclosporine. Restasis has been shown in

Inspire to Present Data at 2007 American Academy of Allergy ...  -  Feb 23, 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Drying time  -  Jan 29, 2007
Odessa American,Colorado Eye Associates recently took part in a clinical study examining an alternative medicine to Restasis. Results are still being gathered.

No Earnings Face-Lift Needed For Allergan  -  Jan 31, 2007
Motley FoolThe company's shares have made many investors quite wealthy, climbing more than 1600% since 1990 with hit products such as Botox and the Restasis eye-drop

Allergan to Buy Swiss Maker  -  Feb 22, 2007
Wall Street Journal (subscription),...used in more than 250000 procedures world-wide, is currently the second-fastest growing product within Allergan, after its Restasis dry-eye treatment.

Surgeon: Early treatment key to avoiding dry eye progression  -  Feb 19, 2007
OSN SuperSite (subscription),..."There is a new tear available for the mild to moderate patient that complements the use of Restasis (cyclosporine ophthalmic emulsion, Allergan)," Dr. Chu

Inspire may license therapy  -  Feb 16, 2007
Durham Herald Sun,Inspire's revenues are generated by its agreement with Allergan to co-promote two of the firm's eye treatments, Elestat and Restasis.

Allergan's profit falls 2.4%  -  Feb 1, 2007
Los Angeles Times,Allergan has been broadening the line, which includes the dry-eye treatment Restasis and the glaucoma medicine Lumigan. Combigan, another Allergan treatment

Allergan Reports Fourth Quarter Operating Results  -  Jan 31, 2007
Genetic Engineering News (press release),RESTASIS(R) product net sales between $320 million and $340 million. -- BOTOX(R) product net sales between $1100 million and $1145 million.

Dry eyes and dry mouth can be evidence of immune attack  -  Jan 27, 2007
Pioneer Press,Restasis eyedrops, which prod the tear glands into action, can be quite helpful. They're not available in all countries. Eye doctors can plug tear ducts,

Inspire provides Cystic Fibrosis clinical program update  -  Jan 16, 2007
Carolina Newswire (press release),Inspire’s US specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine

Inspire Announces Dry Eye Program Update  -  Jan 4, 2007
PharmaLive.com (press release),Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine

Inspire says to meet with FDA over dry eye drug  -  Jan 4, 2007
ReutersInspire, a biotechnology company whose sales force promotes Elesta for allergic conjunctivitis and Restasis for dry eye, did not give the date of its

Rockin' the night away  -  Dec 29, 2006
Arizona Daily Star,And someone told me his late-late-late-late-late night talk show is still on, somewhere between the Restasis ads and the Ron Popeil infomercials.

Inspire to meet with regulators in Feb.  -  Jan 5, 2007
News & Observer,Restasis, a dry-eye drug developed by California-based Allergan, "endured a similarly difficult path to approval," Fein wrote.

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 5, 2006
Business Wire (press release),...s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine ophthalmic ...

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 5, 2006
PharmaLive.com (press release),Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ...

Inspire has loss despite revenue growth  Nov 7, 2006
...had total third quarter revenue of $9.7 million produced by co-promotion revenues of $5.4 million from sales of Elestat and $4.3 million from sales of Restasis ... -Durham Herald Sun, Inspire Reports Third Quarter 2006 Financial Results  Nov 7, 2006
Co-promotion revenue on net sales of Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for the third quarter of 2006 was $4.3 million, an increase of 109 ... -PharmaLive.com (press release), Allergan Will Buy French Firm  Nov 1, 2006
Sales of its dry-eye prescription drug, Restasis, lagged behind expectations, a disappointment the company blamed on a diversion of sales-force attention to ... -Wall Street Journal (subscription), Mixed Outlook From Allergan  Nov 1, 2006
Allergan also decreased its sales estimate for its eye drug Restasis to between $265 million and $275 million from its previous guidance of between $280 ... -TheStreet.com Inspire Announces Progress in Cystic Fibrosis Program  Nov 3, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -Genetic Engineering News (press release), Inspire and FAES Farma Announce Licensing Agreement for New Oral ...  Nov 2, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -PipelineReview.com (press release), Inspire Announces Progress in Cystic Fibrosis Program  Nov 3, 2006
...s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine ophthalmic ... -Business Wire (press release), Inspire and FAES Farma Announce Licensing Agreement for New Oral ...  Oct 31, 2006
...s US specialty sales force promotes Elestat ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine ophthalmic ... -Business Wire (press release), Allergan Reports Third Quarter Operating Results  Nov 1, 2006
...million. -- Allergan is decreasing the expected range of RESTASIS(R) product net sales to between $265 million and $275 million. ... -PharmaLive.com (press release), Inspire Announces Webcasts of Presentations at UBS and Noble ...  Sep 19, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -Business Wire

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 6, 2006
dBusinessNews Triad (press release),Inspire’s US specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 5, 2006
PipelineReview.com (press release),Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine

Inspire Announces Webcast of Presentation At CE Unterberg, Towbin ...  Jul 5, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -Business Wire

Las Vegas Tops National Dry Eye Hot Spots List: First Rankings ...  Jun 28, 2006
RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% is the first and only prescription eye drop that is believed to increase your eyes' natural ability to ... -Medical News Today

D-FW is left high and dry in eye study  Jul 6, 2006
...than the others. None did. "Then they told me there was a new medicine on the market, Restasis," Ms. LaVoy said. "Before, my eyes ... -Dallas Morning News (subscription)



Allergan won't be alone shedding tears  May 14, 2006
That's due in large part to promotional efforts, such as Allergan's support for its Restasis prescription eye drops for dry eye. ... - OCRegister

Dry eye syndrome can be eased  May 16, 2006
...warm compresses and lid scrubs. Then there's Restasis, a new drug, the first prescription out for dry eye. We reserve this for more ... - Indianapolis Star

Inspire Reports First Quarter 2006 Financial Results; Co-Promotion ...  May 9, 2006
2006 included $1.3 million from net sales of Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and $2.9 million from net sales of Restasis(R) (cyclosporine ... - Business Wire

Inspire shares slip on wider 1Q loss  May 9, 2006
Street expectations with $5.5 million in first quarter revenue, most of which came from the company's co-promotion of eye drop products Elestat and Restasis. ... - Triangle Business Journal

Inspire Pharmaceuticals’ Revenues Jump, But So Do Expenses  May 9, 2006
...company said Tuesday. Sales of eye treatment drugs Elestat and Restasis climbed to $1.3 million and $2.9 million. The company also ... - Local Tech Wire

Itchy, Burning Eyes Can be Sign of Dry Eye Syndrome  May 1, 2006
...involves placing filter-paper strips under the lower eyelids to measure the rate of tear production, ophthalmologists may also prescribe Restasis, the only ... - Newswise

Inspire Announces Date for Conference Call and Webcast to Discuss ...  Apr 25, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05 ... - Genetic Engineering News

Allergan Reports First Quarter Operating Results; Pharmaceutical ...  May 3, 2006
Alphagan P, Alphagan and Combigan $71.0 $66.7 $4.3 $5.2 $(0.9) Lumigan 72.9 62.0 10.9 12.1 (1.2) Other Glaucoma 4.4 4.6 (0.2) (0.1) (0.1) Restasis 66.1 37.3 ... - Genetic Engineering News

Inspire reports wider loss  May 9, 2006
...ago. Higher sales of the dry-eye treatment Elestat and the allergy treatment Restasis accounted for part of the revenue increase. ... - News & Observer

NPS Pharmaceuticals Reports First Quarter 2006 Operating Results  May 2, 2006
...to market research, educational and commercial activities associated with PREOS and our promotional activities associated with Kineret(R) and Restasis(R), a ... - MSN Money

NPS Pharmaceuticals Reports First Quarter 2006 Operating Results  May 2, 2006
...to market research, educational and commercial activities associated with PREOS and our promotional activities associated with Kineret® and Restasis®, a $2.7 ... - Yahoo! News





UPDATE 2-Allergan sees 2006 profit in line with Street  Mar 27, 2006
...of Inamed Corp., on Monday forecast 2006 profit in line with Wall Street's view, helped by sales of its Botox wrinkle treatment and its Restasis eye drug. ... - Reuters

Inspire Announces Outcome of FDA Meeting on Dry Eye Program ...  Mar 28, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05 ... - Genetic Engineering News

Glaxo May Pay Sirna More Than $700 Mln for Lung Drugs (Update2)  Apr 3, 2006
29 that it's working with Allergan Inc., the maker of the dry-eye medicine Restasis, to develop treatments for age-related macular degeneration and other eye ... - Bloomberg

AllAboutVision.com Launches ``Ask the Dry Eye Doctor'' to Assist ...  Apr 5, 2006
..."Ask the Dry Eye Doctor" is sponsored by RESTASIS(R), a prescription eye drop that helps increase the body's natural ability to produce tears that may be ... - Business Wire

Allergan Announces 2006 Financial Guidance and Investor Call  Mar 27, 2006
...million. -- Lumigan(R) sales between $280 million and $300 million. -- Restasis(R) sales between $270 million and $290 million. -- Botox ... - Genetic Engineering News

Inspire to Present at Southeast Invest 2006 Conference  Mar 31, 2006
0.05%. Inc. Elestat and Restasis are trademarks owned by Allergan. For more information on Inspire, visit www.inspirepharm.com. preliminary ... - dBusinessNews Triangle



Inspire Reports Fourth Quarter and Full Year 2005 Financial ...  Feb 28, 2006
Fiscal 2005 reflects the first complete year of co-promotion revenue of Elestat(R) and Restasis(R), products the Company co-promotes in the United States under ... - Genetic Engineering News,

What Is Dry Eye Syndrome?  Feb 6, 2006
Another treatment that goes one step further involves the application of Restasis (cyclosporine) eye drops, which effectively enhance tear production. ... - DailyIndia.com,

More Americans report dry-eye symptoms amid increasing air ...  Feb 6, 2006
Called Restasis, the drug was developed to combat dry-eye syndrome. Kornilow says the prescription has been a good option for some of his dry-eye patients. ... - Hagerstown Morning Herald,

Allergan shares off as Botox slows  Feb 2, 2006
Quarterly sales of its eye drug Restasis came in better-then-expected at $53 million, compared with $34 million a year earlier. ... - Reuters

Inspire to Present at Deutsche Bank Small Cap Growth Conference  09 Feb 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05 ... - Genetic Engineering News

What Is Dry Eye Syndrome?  Feb 6, 2006
Another treatment that goes one step further involves the application of Restasis (cyclosporine) eye drops, which effectively enhance tear production. ... - DailyIndia.com

More Americans report dry-eye symptoms amid increasing air ...  Feb 6, 2006
Called Restasis, the drug was developed to combat dry-eye syndrome. Kornilow says the prescription has been a good option for some of his dry-eye patients. ... - Hagerstown Morning Herald

Combating Dry Eye  Jan 26, 2006
...additional treatment. He recommends a new eye drop called "Restasis," which helps anyone who suffers from dry eyes. Varley said ... - 13WHAM-TV

Allergan shares off as Botox slows  Feb 2, 2006
Quarterly sales of its eye drug Restasis came in better-then-expected at $53 million, compared with $34 million a year earlier. ... - Reuters

Allergan shares off as Botox slows  Feb 2, 2006
Quarterly sales of Allergan's eye drug Restasis came in better than expected at $53 million, compared with $34 million a year earlier. ... - Reuters

(PZ) Novartis Delivers Strong Performance with Record Results in ...  Jan 18, 2006
One-time gains of USD 231 million from the divestment of product rights for Cibadrex/Cibacen in Europe and the sale of license rights for Restasis(r) partially ... - Houston Chronicle

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional